Key result
Postprocedural cardiac troponin T elevation ≥25× the upper limit of normal was significantly associated with 3-month mortality after nonemergent PCI (HR 4.53; 99% CI 1.59-12.9; P<0.001).
Why the study?
Does postprocedural cardiac troponin T elevation above specific thresholds predict 3-month mortality in patients undergoing nonemergent PCI with normal baseline cTnT?
Cohort (n=5,268)
Does postprocedural cardiac troponin T elevation above specific thresholds predict 3-month mortality in patients undergoing nonemergent PCI with normal baseline cTnT?
A postprocedural cTnT elevation of ≥25× ULN is the optimal threshold for predicting 3-month mortality after nonemergent PCI in patients with normal baseline cTnT.
Answers are grounded in this paper and cite their sources.
May flag higher short-term mortality after nonemergent PCI; leaves open whether thresholds should guide postprocedural care.
BACKGROUND: There is controversy about the diagnostic and prognostic significance of percutaneous coronary intervention-related myocardial infarction, especially with the use of cardiac troponin T (cTnT). This analysis was designed to address the question of the presence and the level of a prognostic cTnT threshold. METHODS AND RESULTS: We evaluated 5268 consecutive patients who underwent nonemergent percutaneous coronary intervention between 2000 and 2009 with a preprocedural cTnT level below the upper limit of normal (ULN, ≤0.01 ng/mL). Postprocedural cTnT and creatine kinase-MB mass levels (ULN, 6.7 ng/mL in men and 3.8 ng/mL in women) were found to be associated with 3-month mortality in Cox proportional hazard models (hazard ratio per doubling of cTnT, 1.24; 95% confidence interval, 1.08-1.43; P=0.003 and hazard ratio per doubling of creatine kinase-MB, 1.30; 95% confidence interval, 1.05-1.60; P=0.018), adjusted for the Mayo Clinic risk scores for in-hospital and postdischarge mortality. The optimal prognostic threshold for 3-month mortality was 25× ULN for cTnT (hazard ratio, 4.53; 99% confidence interval, 1.59-12.9; P<0.001), which provided similar information as a value of 5× ULN for creatine kinase-MB (hazard ratio, 4.31; 99% confidence interval, 1.27-14.6; P=0.002). The cumulative mortality rate was 0.6% at 91 days. CONCLUSIONS: A significant association of postpercutaneous coronary intervention cardiac biomarker elevation with a small number of postpercutaneous coronary intervention outcomes was noted for the early (first 91 days) follow-up period with an identifiable optimal threshold of 25× ULN (0.25, ng/mL) for cTnT, which provided similar early outcome information as a cutoff of 5× ULN for creatine kinase-MB.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2014) conducted a cohort in Nonemergent percutaneous coronary intervention (n=5,268). Postprocedural cardiac troponin T elevation ≥25× ULN vs. Lower postprocedural cardiac troponin T levels was evaluated on 3-month mortality (HR 4.53, 95% CI 1.59-12.9, p=<0.001). Postprocedural cardiac troponin T elevation ≥25× the upper limit of normal was significantly associated with 3-month mortality after nonemergent PCI (HR 4.53; 99% CI 1.59-12.9; P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: